Back to top
more

Rigel Pharmaceuticals (RIGL)

(Delayed Data from NSDQ)

$1.19 USD

1.19
828,711

-0.03 (-2.46%)

Updated May 7, 2024 04:00 PM ET

After-Market: $1.20 +0.01 (0.84%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher

Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

    Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

    Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and 489.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

      Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

        Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session

        Shares of Rigel Pharmaceuticals (RIGL) rose over 8% yesterday.

          Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug

          Rigel's (RIGL) stock plunges 13% on the failure of a phase II study on lead drug, fostamatinib, in patients with IgA nephropathy (IgAN).

            Options Traders Expect Huge Moves in Rigel Pharmaceuticals (RIGL) Stock

            Rigel Pharmaceuticals (RIGL) needs investors to pay close attention to the stock based on moves in the options market lately.

              Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

              Rigel Pharmaceuticals (RIGL) needs investors to pay close attention to the stock based on moves in the options market lately.

                Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher

                Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

                  Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA

                  Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia

                    Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

                    Investors in Rigel Pharmaceuticals, Inc. (RIGL) need to pay close attention to the stock based on moves in the options market lately.

                      Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug

                      Rigel Pharmaceuticals, Inc. (RIGL) recently announced that it has filed a new drug application (NDA) to the FDA, for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment immune thrombocytopenia (ITP).

                        Swarup Gupta headshot

                        5 Top Breakout Stocks to Boost Your Portfolio

                        If properly implemented, such a strategy could deliver impressive returns.

                          Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?

                          Rigel (RIGL) could be an interesting play for investors as it sees solid activity on the earnings estimate revision.

                            Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher?

                            As of late, it has definitely been a great time to be an investor in Rigel Pharmaceuticals, Inc. (RIGL).

                              Swarup Gupta headshot

                              5 Cheap Breakout Stocks for Superb Returns

                              The technique identifies those stocks whose prices are fluctuating within a specific band.

                                Sanghamitra Saha headshot

                                Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?

                                Inside the changes in portfolio constituents of two BioShares Biotech ETFs.